Amgen (AMGN) Q4 2025 (USD): Adj. EPS 5.29 (exp. 4.73), Revenue 9.87bln (exp. 9.47bln)

Amgen's Q4 2025 results exceeded expectations, with both adjusted EPS and revenue coming in higher than anticipated.

Newsquawk StaffPublished On the live feed at 10 more headlines followed before this page went public
Newsquawk headlinesUTC

Enphase Energy Inc. (ENPH) Q4 2025 (USD) Adj. EPS 0.71 (exp. 0.59), Revenue 343mln (exp. 342mln)

Texas Instruments (TXN) reportedly in advanced talks to buy Silicon Laboratories (SLAB) for roughly USD 7bln, FT reports

Amgen (AMGN) Q4 2025 (USD): Adj. EPS 5.29 (exp. 4.73), Revenue 9.87bln (exp. 9.47bln)

Iran says planning has been carried out to hold negotiations with the US over the coming days

Iran’s foreign ministry spokesperson says consultations for venue of talks with the US are underway, Nour News reports

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
  • Operating income 4.0bln (exp. 3.64bln).

Outlook

  • FY adj. EPS 21.60-23.00 (exp. 22.13).
  • FY revenue 37-38.4bln (exp. 37.2bln).
  • FY26 share repurchases not to exceed USD 3bln.
  • To initiate phase 3 studies of maritide in people living with type 2 Diabetes in 2026
Context

This positive performance, coupled with an optimistic forward outlook on annual EPS and revenue, suggests strong operational momentum and could bolster confidence among investors, particularly as the company initiates new phase 3 studies that may enhance its pipeline.

Related headlines

The whole workspace, free to try.

Try it free